|
Technology: Emulsiphan Selective Delivery Platform |
Even the most potent and effective cancer drug must be able to penetrate a tumor mass, be distributed among the cancer cells, and be delivered to the correct molecular target in vivo. Overcoming these delivery hurdles often requires higher systemic dosing, increasing the risk of deleterious side effects from the cancer drug’s effects on normal tissues. Our Emulsiphan Drug Delivery platform is comprised of novel compositions that can selectively deliver an anticancer drug contained within these compositions into cancer cells when systemically administered. Our lead compound in this platform, EmPAC, is an Emulsiphan-based composition containing the potent antimitotic agent paclitaxel.
The Emulsiphan composition is a non-liposomal, stable oil water lipid nanoemulsion selectively taken up by cancer cells by exploiting their increased demand for nutrients, non-polar lipids and specific fatty acids. Similar compositions have been evaluated in tumor-imaging applications, where a ratio of tumor uptake versus normal tissue ratio of 500-1000: 1 has been reported.
|
